How Haya Therapeutics is targeting the dark genome to treat fibrotic disease
When Samir Ounzain watched Jurassic Park at the age of 10, he knew he wanted to become a molecular biologist. Now he has a company that is trying to change the way we think about the so-called dark genome or noncoding DNA.
Previously thought of as “junk” DNA, this part of the genome, which makes up around 98% of our DNA, is now kn...
Previously thought of as “junk” DNA, this part of the genome, which makes up around 98% of our DNA, is now kn...